AgomAb Therapeutics NV (AGMB) Stock Price & Analysis

AgomAb Therapeutics NV (AGMB) is trading at USD 5.74, down 3.04% today, as of November 18, 2026 at 20:52 UTC (US market open; quotes may be delayed), according to Nexqual market data.

AGMB last closed at USD 5.92; today's session has ranged USD 5.7–6.25 on volume of 97,063 shares. Market capitalization is $282.68M, with a 52-week range of USD 5.5–17.82 (NMS). Source: Nexqual, retrieved November 18, 2026 at 20:53 UTC.

What changed for AGMB since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/AGMB.md

Key facts (AGMB)

Insider purchases (SEC Form 4, open-market, last ~7 months) (AGMB)

7 purchases, $592K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Trade dateInsiderRoleSharesValueAvg priceInsider type
2026-11-13Epstein David RDirector14,980$89K5.92Too little history (no open-market trades in 2023–2025)
2026-11-05Epstein David RDirector15,000$104K6.9Too little history (no open-market trades in 2023–2025)
2026-10-21Epstein David RDirector10,000$89K8.88Too little history (no open-market trades in 2023–2025)
2026-10-08Epstein David RDirector5,000$45K8.9Too little history (no open-market trades in 2023–2025)
2026-10-05…2026-10-06Epstein David RDirector10,000$86K8.63Too little history (no open-market trades in 2023–2025)
2026-10-06Kemula Pierre Thadee VictorChief Financial Officer10,000$86K8.59Too little history (no open-market trades in 2023–2025)
2026-10-05…2026-10-06Knotnerus Tim JasperChief Executive Officer11,000$94K8.58Too little history (no open-market trades in 2023–2025)

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (AGMB)

Consensus Buy (mean 1.57 on a 1–5 scale), 7 analysts; mean target USD 37.67 (low 28, high 60).

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-08-25Piper SandlerInitiatedOverweight$60
2026-08-19Cantor FitzgeraldInitiatedOverweight
2026-07-23B. Riley SecuritiesInitiatedBuy$34

Total return (dividends reinvested) (AGMB)

1Y (from 2026-02-06)5Y (from 2026-02-02)
Total return-60.8%-60.8%
S&P 500 (SPY)+11.9%+66.7%
Per year——
Volatility (annualized)91.9%74.7%
Max drawdown-67.8% (Jun 2026→Nov 2026)-64.2% (Feb 2026→Nov 2026)

Dividends (AGMB)

AGMB paid no cash dividend in the last five years.

Short interest (AGMB)

920,851 shares sold short, 2.26% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,001,145 shares (-8.0%). Days to cover: 6.1 (short shares ÷ average daily volume).

AGMB recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 2026Schedule 13G/ARedmile Group, LLC, Jeremy C. Green: 3.5% of shares, passive 5%+ holder (amended)
Oct 13, 20266-KCurrent report (foreign issuer) · period ended Oct 13, 2026
Oct 1, 20266-KCurrent report (foreign issuer) · period ended Oct 1, 2026
Sep 14, 20266-KCurrent report (foreign issuer) · period ended Sep 14, 2026
Sep 11, 20266-KCurrent report (foreign issuer) · period ended Sep 11, 2026
Aug 10, 20266-KCurrent report (foreign issuer) · period ended Aug 10, 2026
Aug 6, 20266-KCurrent report (foreign issuer) · period ended Aug 6, 2026

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

AGMB analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Sep 2026)$-0.36$-0.48+$0.12$03
Next quarter (ends Dec 2026)$-0.42$-0.54+$0.13$03
Current fiscal year (ends Dec 2026)$-1.81$-1.85+$0.05$06
Next fiscal year (ends Dec 2027)$-2.02$-2.08+$0.06$06

Key Statistics (as of November 18, 2026 at 20:53 UTC)

PriceUSD 5.74
Change▼ 3.04% (down)
Previous CloseUSD 5.92
OpenUSD 6
Day RangeUSD 5.7 – 6.25
52-Week RangeUSD 5.5 – 17.82
Volume97,063 shares
Market Cap$282.68M
ExchangeNMS

Technical Analysis (AGMB)

Nexqual's technical model rates AGMB "SELL" based on 2 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:53 UTC.

Overall SignalSELL
RSI (14)26.17 (oversold)
vs SMA50Below (USD 9.01)
MACD-0.88 (negative)

Analyst Ratings (AGMB)

Wall Street analysts rate AGMB "Buy" based on 7 analysts, with a mean price target of USD 37.67 (range USD 28–60), per Nexqual as of November 18, 2026 at 20:53 UTC.

Consensus RatingBuy
Analyst Count7
Mean TargetUSD 37.67
High TargetUSD 60
Low TargetUSD 28
Buy / Hold / Sell7 / 0 / 0

Earnings (AGMB)

EPS EstimateUSD -0.37
Revenue Estimate$0

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financials & Fundamentals (AGMB)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
Debt / Equity0
Current Ratio12.88
Total Cash$251.98M
Total Debt$1.14M

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Financial Health Score (AGMB)

Nexqual rates AgomAb Therapeutics NV's overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:53 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetStrong — EUR 252M cash vs EUR 1M debt, net cash position
Cash FlowWeak — Operating cash flow -EUR 57M (TTM)
EfficiencyMixed — No data

Ownership (AGMB)

Insider Ownership+10.27%
Institutional Ownership+53.68%
Shares Outstanding49.25M
Float19.32M
Short % of Float+2.26%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Leadership (AGMB)

AgomAb Therapeutics NV is led by Tim Knotnerus MSc, CEO & Executive Director, per Nexqual as of November 18, 2026 at 20:53 UTC.

CEO & Executive DirectorTim Knotnerus MSc
Chief Financial OfficerPierre Kemula B.Sc.
Vice President of Investor RelationsSofie Van Gijsel

Major Backers & Investors (AGMB)

Notable institutional backers of AgomAb Therapeutics NV include Eqt Fund Management S.a R.l., Sanofi, Cormorant Asset Management, LP, according to Nexqual as of November 18, 2026 at 20:53 UTC.

Active Investors

InvestorStake
Eqt Fund Management S.a R.l.10.44%
Sanofi5.65%
Cormorant Asset Management, LP5.01%
Pfizer Inc4.37%
TCG Crossover Management, LLC3.7%
Nantahala Capital Management, LLC3.55%
Redmile Group, LLC3.53%
Federated Hermes, Inc.3.28%

Source: Nexqual, November 18, 2026 at 20:53 UTC.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 97.7▲ 0.93%
BLTEBelite Bio, IncUSD 156.45▼ 0.81%
ORKAOruka Therapeutics, Inc.USD 95.68▼ 0.67%
IBRXImmunityBio, Inc.USD 6.71▲ 7.11%
IMVTImmunovant, Inc.USD 33.24▲ 0.09%
CGONCG Oncology, Inc.USD 79.85▲ 1.15%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:53 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt